证券代码：603566 证券简称：普莱柯 公告编号：2025-033 至2025 年 9 月 16 日 普莱柯生物工程股份有限公司 关于召开2025年第一次临时股东大会的通知 召开地点：河南省洛阳市洛龙区政和路 15 号公司二楼会议室 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (五)网络投票的系统、起止日期和投票时间。 重要内容提示： 网络投票系统：上海证券交易所股东大会网络投票系统 召开的日期时间：2025 年 9 月 16 日 14 点 00 分 网络投票起止时间：自2025 年 9 月 16 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (六)融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者 的投票，应按照《上海证券交易所上市公司自律监管指引第 ...

证券日报网讯 8月29日晚间，普莱柯发布公告称，公司于近日收到华泰联合证券有限责任公司（简 称"华泰联合证券"）出具的《关于更换普莱柯生物工程股份有限公司非公开发行股票持续督导保荐代表 人的函》。华泰联合证券作为公司2021年度非公开发行股票的保荐机构，原委派甄清先生和张若思先生 作为持续督导保荐代表人。现张若思先生因个人工作变动，不能继续担任持续督导期的保荐代表人，为 保证公司持续督导工作的有序进行，华泰联合证券现委派韩斐冲先生接替张若思先生担任持续督导保荐 代表人，继续履行持续督导职责。 （编辑 姚尧） ...

证券代码：603566 证券简称：普莱柯 公告编号：2025-037 普莱柯生物工程股份有限公司 关于变更持续督导保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 普莱柯生物工程股份有限公司（以下简称"公司"）于近日收到华泰联合证 券有限责任公司（以下简称"华泰联合证券"）出具的《关于更换普莱柯生物工 程股份有限公司非公开发行股票持续督导保荐代表人的函》。华泰联合证券作为 公司 2021 年度非公开发行股票的保荐机构，原委派甄清先生和张若思先生作为 持续督导保荐代表人。现张若思先生因个人工作变动，不能继续担任持续督导期 的保荐代表人，为保证公司持续督导工作的有序进行，华泰联合证券现委派韩斐 冲先生（简历详见附件）接替张若思先生担任持续督导保荐代表人，继续履行持 续督导职责。 韩斐冲先生，现任华泰联合证券投资银行业务线总监，保荐代表人。曾参与 完成的项目包括：北玻股份、容百科技、设研院、隆华科技、长青集团、江阴银 行、佳沃股份等再融资项目，电科数字、王府井、天山铝业等重大资产重组项目， 在保荐业务执业过程中严格遵 ...

Market Overview - The animal health sector experienced a decline of 0.5% on August 29, with *ST Lvkang leading the drop [1] - The Shanghai Composite Index closed at 3857.93, up 0.37%, while the Shenzhen Component Index closed at 12696.15, up 0.99% [1] Individual Stock Performance - The top performer in the animal health sector was Qudongli (code: 838275), with a closing price of 11.87 and an increase of 7.23% [1] - Other notable gainers included Yongshun Biological (code: 839729) with a 1.34% increase and Ruipu Biological (code: 300119) with a 0.81% increase [1] - Conversely, *ST Lvkang (code: 002868) saw a significant decline of 3.24%, closing at 26.32 [2] Trading Volume and Capital Flow - The total net outflow of main funds in the animal health sector was 53.36 million yuan, while retail funds saw a net inflow of 29.48 million yuan [2] - The trading volume for Qudongli was 92,700 hands, with a transaction amount of 108 million yuan [1] Fund Flow Analysis - *ST Lvkang experienced a net outflow of 11.85 million yuan from main funds, representing a 24.27% net share [3] - In contrast, retail funds for *ST Lvkang saw a net inflow of 7.44 million yuan, accounting for 15.25% of its total [3] - Other companies like Shenglian Biological and Zhongmu Co. also faced net outflows from main funds, indicating a trend of capital withdrawal in the sector [3]

Group 1 - The company, Pulaike (SH 603566), held its 19th meeting of the 5th board of directors on August 28, 2025, to review the proposal for the full and summary report of the 2025 semi-annual report [1] - For the year 2024, the company's revenue composition is as follows: veterinary biological products account for 96.44%, functional health products account for 1.79%, income from technology licensing or transfer accounts for 0.94%, and other businesses account for 0.83% [1]

Core Viewpoint - The company, Pulaike Biological Engineering Co., Ltd., has announced the use of part of its idle raised funds for cash management to improve fund efficiency and ensure project safety while increasing investment returns [1][2]. Group 1: Fundraising and Management - The company has raised a total of 897,999,976.34 yuan through a non-public offering of 31,420,573 shares at a price of 28.58 yuan per share, with a net amount of 885,820,523.22 yuan after deducting issuance costs [1]. - As of June 30, 2025, the company has utilized 3,884,676.19 yuan of the raised funds, leaving a balance of 201,103,541.25 yuan [1]. Group 2: Cash Management Details - The investment purpose is to enhance the efficiency of idle raised funds, ensure project construction and fund safety, and increase investment returns [2]. - The investment limit is set at no more than 210 million yuan, allowing for single or cumulative rolling cash management within a one-year period [2]. - The funds will be sourced from temporarily idle raised funds and will be invested in low-risk, high-liquidity financial products such as structured deposits and large-denomination certificates of deposit [2]. Group 3: Decision-Making and Oversight - The investment decision does not require shareholder meeting approval and is authorized to the company's legal representative or their authorized personnel [2]. - The company has implemented several risk control measures, including pre-planning by the finance department, ongoing management, and post-tracking accounting [2]. - The supervisory board and independent directors have the authority to oversee and audit the cash management process, ensuring compliance with necessary legal procedures [3].

Core Viewpoint - The company has approved a plan to use up to 210 million yuan of temporarily idle raised funds for cash management, focusing on low-risk and highly liquid financial products [1] Group 1 - The decision was made during the 19th meeting of the fifth board of directors and the 13th meeting of the fifth supervisory board [1] - The investment will be concentrated in principal-protected financial products such as structured deposits and large-denomination certificates of deposit [1] - The resolution is valid for 12 months, allowing funds to be used on a rolling basis within the approved limit [1] Group 2 - The company emphasizes that the investment risks are controllable, although they may still be affected by market fluctuations [1]

华泰联合证券有限责任公司 关于普莱柯生物工程股份有限公司 使用部分闲置募集资金进行现金管理的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"） 作为普莱柯生物工程股份有限公司（以下简称"普莱柯"或"公司"）2021 年 度非公开发行 A 股股票的保荐机构，根据《证券发行上市保荐业务管理办法》 《上海证券交易所股票上市规则》《上市公司募集资金监管规则》《上海证券交 易所上市公司自律监管指引第 1 号——规范运作》及《上海证券交易所上市公司 自律监管指引第 11 号——持续督导》等相关法律法规的规定，对普莱柯本次使 用部分闲置募集资金进行现金管理事项进行了审慎核查，具体核查情况如下： 一、使用闲置募集资金进行现金管理基本情况 （一）募集资金的基本情况 经中国证券监督管理委员会《关于核准普莱柯生物工程股份有限公司非公开 发行股票的批复》（证监许可〔2022〕1251 号）核准，普莱柯生物工程股份有 限公司（以下简称"公司"）非公开发行 31,420,573 股的人民币普通股（A 股）， 发行价格为 28.58 元/股，募集资金总额为 897,999,976.34 元，扣除发行费用后募 集资 ...

Group 1 - The company reported a total operating revenue of 559 million yuan for the first half of 2025, representing a year-on-year increase of 15.79% [1] - The net profit attributable to shareholders of the parent company reached 116 million yuan, showing a year-on-year growth of 57.12% [1] - Basic earnings per share were 0.34 yuan [1] Group 2 - The company plans to distribute a cash dividend of 2 yuan (including tax) for every 10 shares to all shareholders [1]

证券代码：603566 证券简称：普莱柯 公告编号：2025-031 普莱柯生物工程股份有限公司 关于使用部分闲置自有资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、现金管理概况 （一）现金管理目的 公司目前经营情况稳定、财务状况稳健，为提高公司资金使用效率，在保证 日常经营资金需求和资金安全的前提下，公司拟使用部分闲置自有资金进行现金 管理，以更好实现公司资金的保值增值，为公司和股东获取较好的投资回报。 现金管理产品：安全性高、流动性好、保本或稳健型理财产品，本次拟 购买的理财产品主要为大额存单 现金管理额度及期限：普莱柯生物工程股份有限公司（以下简称"公司"） 拟使用不超过人民币 2.5 亿元闲置自有资金进行现金管理，在上述额度 内，该类资金可以单笔或分笔进行单次或累计滚动的现金管理。使用期 限自第五届董事会第十九次会议、第五届监事会第十三次会议审议通过 之日起 12 个月内有效。 履行的审议程序：公司于 2025 年 8 月 28 日召开第五届董事会第十九次 会议、第五届监事会 ...